I-MAB (IMAB) Interest Expense : $-0.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. I-MAB's interest expense for the six months ended in Dec. 2023 was $ -0.07 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. I-MAB's Operating Income for the six months ended in Dec. 2023 was $ -77.07 Mil. I-MAB's Interest Expense for the six months ended in Dec. 2023 was $ -0.07 Mil. I-MAB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

I-MAB Interest Expense Historical Data

The historical data trend for I-MAB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Interest Expense Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.43

-0.15

-0.10

I-MAB Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial								-	-	-	-0.03	-0.07

I-MAB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.10 Mil.

I-MAB (NAS:IMAB) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

I-MAB's Interest Expense for the six months ended in Dec. 2023 was $-0.07 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-77.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $11.49 Mil.

I-MAB's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

I-MAB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

I-MAB (IMAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124

Website

https://www.i-mabbiopharma.com

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.